Abdul Mannan: Not All Type 1 VWD Starts in the VWF Gene
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“‘The endothelial cell has plenty of VWF. It just can’t get it out the door.’
Most type 1 VWD gets explained one of two ways: the endothelial cell makes too little VWF, or it clears VWF too fast.
A 2025 Blood paper adds a third mechanism, and it changes how I think about unexplained low VWF.
Endothelial cells store VWF inside Weibel-Palade bodies, ready to release on demand.
Getting it out needs a docking crew: Rab27A and Rab3 GTPases, switched on by a protein called MADD.
Kat et al. showed in 2021 that MADD is the activator for this Rab docking crew (Blood Advances 2021).
Hordijk et al. studied three children with biallelic MADD variants. All had VWF levels of 22-30 IU/dL and no VWF gene mutation.
Their endothelial cells had no MADD protein, low Rab27A and Rab3D activity, and reduced histamine-induced VWF release (Blood 2025).
Same cargo. Same storage unit. Broken alarm system.
I would think about this when you see a type 1 VWD phenotype, a normal VWF gene, and especially any neurodevelopmental or multisystem features alongside the bleeding history.
This is not a first-line test yet.
But it tells us type 1 VWD is not only a VWF gene disease.
It can be a secretion disease too.
Have you seen a low VWF case where the gene test came back clean?”

Other posts from Abdul Mannan on Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series